Thursday, July 10, 2025
  • REPORT A STORY
  • PRIVACY POLICY
  • CONTACT
WITHIN NIGERIA
  • HOME
  • FEATURES
  • NEWS
  • ENTERTAINMENT
  • FACT CHECK
  • MORE
    • VIDEOS
    • GIST
    • PIECE (ARTICLES)
No Result
View All Result
WITHIN NIGERIA
  • HOME
  • FEATURES
  • NEWS
  • ENTERTAINMENT
  • FACT CHECK
  • MORE
    • VIDEOS
    • GIST
    • PIECE (ARTICLES)
No Result
View All Result
WITHIN NIGERIA
No Result
View All Result
  • HOME
  • FEATURES
  • NEWS
  • ENTERTAINMENT
  • FACT CHECK
  • MORE

COVID-19: No vaccine approved yet for clinical trials, says NAFDAC

by Adejayan Gbenga Gsong
April 10, 2020
in National
Reading Time: 3 mins read
A A
0
NAFDAC orders production of Chloroquine for the clinical trial treatment of Coronavirus
Share on FacebookShare on Twitter

The National Agency for Food and Drug Administration and Control,NAFDAC, said yesterday it has not approved any vaccines for clinical trial for coronavirus disease in the country.

NAFDAC said approval for vaccines for clinical trial might not happen before one year to 18 months, after clinical trials must have been conducted in different countries.

According to the agency, this will be followed by rigorous in-country assessment, in line with laid down protocols to further ensure safety and efficacy.

But the agency in a statement by its Director General, Prof Mojisola Adeyeye, said it had given what it called conditional emergency use approval of medical devices (COVID-19) antibody and antigen test kits, PPEs, etc. to companies.

READ ALSO

Democracy Day Turns Protest Day: Nigerians decry hardship, ask Tinubu to fix economy

INTERVIEW: My Reason For Writing “A COUNTRY IN TEARS”—Enugu-based writer explains

OSINACHI: Refusal of governors to sign death sentence makes justice blurry in Nigeria

SPECIAL REPORT: Inside Story Of How Banks, ATM Charges Worsen Nigerians’ Economic Woes

TRIBUTE: Doyin Okupe: Son Of Banker Who Laced Medical Profession, Journalism, Politics With Great Efficiency

The approved antigen test kids, the agency explained, could detect the COVID-19 antigen in patients with or without symptoms.

It also explained that the antibody test kits (IgG/IgM) could be used in COVID-19 confirmed individuals, who could then be tested at the designated centres using the antibody kits, to confirm that they had antibodies and as such might not be infected again.

The statement read: “National Agency for Food and Drug Administration and Control grants conditional emergency use approval of medical devices (COVID-19 Antibody and Antigen Test Kits, PPEs, etc.)

“The National Agency for Food and Drug Administration and Control, pursuant to the powers conferred on it by section 5 of the NAFDAC Act, to regulate and control the manufacture, importation, exportation distribution sale, use and advertisement of medical devices has taken some regulatory steps in the fight against COVID-19.

“The pandemic has necessitated that NAFDAC put measures in place to ensure access to health commodities that have the potential to impact positively on public health outcomes.

“These include, but are not limited to, diagnostics necessary to support public health infrastructure and guide the response necessary to combat and address the pandemic.

“The antibody test kits (IgG/IgM) can be used in COVID-19 confirmed individuals, who can then be tested at the designated centers using the antibody kits, to confirm that they have antibodies and as such may not be infected again. The antigen tests kits on the other hand, can detect the COVID-19 antigen in patients with or without symptoms. The results are only qualitative (positive or negative.)

“There has been a global effort by innovative diagnostic companies to develop test kits to aid in detection of the virus in patients to guide the management of the disease. The agency has recently received many requests for emergency use authorization for some of such diagnostic test kits to support national response.

“NAFDAC has put in place regulatory measures to ensure quality, safety and efficacy criteria are assessed.

“These measures are supported by documentation which include prior registration and approval by reference regulatory authorities, such as those of Japan USA, Germany, Canada, European Medicine Agency, etc.

‘’Registration by the regulatory authority in the country of manufacture; declaration of conformity; and validation/performance evaluation /clinical evaluation report.

“NAFDAC is part of the African Medical Devices Forum (AMDF), a Technical Working Group of African Medical Products Regulatory Harmonization (AMRH) that has a joint secretariat with WHO. Deliberations of the Forum that will be shared with the AMRH Steering Committee for approval and implementation, will further guide NAFDAC. Some of the technical issues that will come out of the deliberations include updates on the list of COVID-19 in vitro diagnostics and medical devices, substandard and falsified commodities and handling of donations.

“NAFDAC will continue to stay abreast of current best global practices in this area and monitor updates to the WHO collated list of medical devices being used by different countries.

“In addition to these requirements, the full approval of any diagnostic/test kit by NAFDAC for COVID-19 will be subject to in-country validation to assess the sensitivity or rate of failure (i.e., indication of false positives), and specificity.

“Failure to comply could lead to revocation of any approval granted for importation of the products and forfeiture of same to the agency for destruction.

“NAFDAC has reduced the registration to approval time from 120 working days to 10 days due to the pandemic. Thus far, the Agency has processed 17 applications using the expedited review process but has only granted emergency approval to seven companies using the criteria listed above.

“The availability of Personal Protective Equipment (PPE) for health care providers is a critical component of the effort to stem the pandemic. These PPEs include gloves, protective goggles, face shields, protective gowns and masks in the form of particulate respirators and surgical masks. These must meet certain technical requirements and specifications to achieve the objective and offer some measure of protection to healthcare providers and limit their exposure to infection.

“Please note, no vaccines have been approved for any clinical trial. That may not happen before one year to eighteen months, after clinical trials must have been conducted in different countries. This will be followed by rigorous in-country assessment in line with laid down protocols to further ensure safety and efficacy.”

RELATED STORYPosts

National

Democracy Day Turns Protest Day: Nigerians decry hardship, ask Tinubu to fix economy

by Sodiq Lawal Chocomilo
June 13, 2025
National

INTERVIEW: My Reason For Writing “A COUNTRY IN TEARS”—Enugu-based writer explains

by Nnadi Christopher Ikechukwu
May 27, 2025

Discussion about this post

POPULAR THIS WEEK

No Content Available
No Content Available
WITHIN NIGERIA

WITHIN NIGERIA MEDIA LTD.

NEWS, MULTI MEDIA

WITHIN NIGERIA is an online news media that focuses on authoritative reports, investigations and major headlines that springs from National issues, Politics, Metro, Entertainment; and Articles.

Follow us on social media:

CORPORATE LINKS

  • About
  • Contacts
  • Report a story
  • Advertisement
  • Content Policy
  • Privacy Policy
  • Terms
 
  • Fact-Checking Policy
  • Ethics Policy
  • Corrections Policy
  • WHO IS WITHIN NIGERIA?
  • CONTACT US
  • PRIVACY
  • TERMS

© 2022 WITHIN NIGERIA MEDIA LTD. designed by WebAndName

No Result
View All Result
  • HOME
  • FEATURES
  • NEWS
  • ENTERTAINMENT
  • FACT CHECK
  • MORE
    • VIDEOS
    • GIST
    • PIECE (ARTICLES)

© 2022 WITHIN NIGERIA MEDIA LTD. designed by WebAndName